Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Hiroaki Umebayashi »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Hiroaki Takeo < Hiroaki Umebayashi < Hiroaki Yamaguchi  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000070 (2008) Shumpei Yokota [Japon] ; Tomoyuki Imagawa ; Masaaki Mori ; Takako Miyamae ; Yukoh Aihara ; Shuji Takei ; Naomi Iwata ; Hiroaki Umebayashi ; Takuji Murata ; Mari Miyoshi ; Minako Tomiita ; Norihiro Nishimoto ; Tadamitsu KishimotoEfficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
000698 (2013) Shumpei Yokota ; Tomoyuki Imagawa ; Masaaki Mori ; Takako Miyamae ; Syuji Takei ; Naomi Iwata ; Hiroaki Umebayashi ; Takuji Murata ; Mari Miyoshi ; Minako Tomiita ; Norihiro Nishimoto ; Tadamitsu KishimotoLong-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
000A59 (2014) Shumpei Yokota [Japon] ; Tomoyuki Imagawa ; Masaaki Mori ; Takako Miyamae ; Syuji Takei ; Naomi Iwata ; Hiroaki Umebayashi ; Takuji Murata ; Mari Miyoshi ; Minako Tomiita ; Norihiro Nishimoto ; Tadamitsu KishimotoLongterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
002778 (2020) Masaki Shimizu [Japon] ; Mao Mizuta [Japon] ; Nami Okamoto [Japon] ; Takahiro Yasumi [Japon] ; Naomi Iwata [Japon] ; Hiroaki Umebayashi [Japon] ; Yuka Okura [Japon] ; Noriko Kinjo [Japon] ; Tomohiro Kubota [Japon] ; Yasuo Nakagishi [Japon] ; Kenichi Nishimura [Japon] ; Mariko Mohri [Japon] ; Masato Yashiro [Japon] ; Junko Yasumura [Japon] ; Hiroyuki Wakiguchi [Japon] ; Masaaki Mori [Japon]Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Hiroaki Umebayashi" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Hiroaki Umebayashi" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Hiroaki Umebayashi
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021